Two studies [113,115] suggest that AKR1B10 is a useful serum biomarker for advanced liver fibrosis and, thereby, the diagnosis of NAFLD/NASH. This evidence concerns the gene AKR1B10 and metabolic dysfunction-associated steatohepatitis.